HRYZ-T101 Injection for HPV18 Positive Solid Tumor

This study is testing an immune cell therapy called HRYZ-T101 in people with HPV18-positive solid tumors (cancers infected with the human papillomavirus type 18) that have stopped responding to standard treatments. This therapy uses the patient's own immune cells that are trained to recognize and attack HPV18-infected cancer cells. **You may be eligible if...** - You are 18 to 75 years old with confirmed HPV18-positive solid cancer (such as cervical cancer) that is recurrent or metastatic - Your cancer has not responded to prior treatments and there are no other effective options - You carry a specific immune protein type called HLA-DRB1*0901 - Your overall health (ECOG ≤1) and organ function are adequate **You may NOT be eligible if...** - You have received prior cell therapy - You are HIV positive, have active hepatitis B or C, or syphilis - You have active autoimmune disease - You have had active tuberculosis in the past year - You have symptomatic brain metastases - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.